EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension

Sihem Ait-Oudhia iD, David Jaworowicz, Ziheng Hu iD, Sébastien Bihorel iD, Shuai Hu iD, Budda Balasubrahmanyam, Bipin Mistry, Janethe de Oliveira Pena iD, Larissa Wenning, Ferdous Gheyas iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Sihem Ait-Oudhia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Models, Biological, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotatercept is a breakthrough, first‐in‐class biologic, that is FDA‐approved for the treatment of pulmonary arterial hypertension (PAH). A population pharmacokinetic (PopPK) model was developed using data from two phase 1 studies in healthy participants, and two phase 2 studies and one phase 3 study in participants with PAH. The pooled sotatercept PK data encompassed single intravenous (IV) or subcutaneous (SC) doses ranging from 0.01 to 3.0 mg/kg, as well as multiple SC doses ranging from 0.03 to 1.0 mg/kg, with PK samples collected up to a maximum of ~150 weeks following Q3W and Q4W dosing regimens. The final PopPK analysis included 350 participants, with 30 and 320 participants receiving sotatercept IV and SC, respectively. A two‐compartment model with a first‐order absorption rate constant and a linear disposition from central compartment well‐described sotatercept PK. The estimated bioavailability is ~66%; bioavailability, clearance (CL), and central volume (VC) have low to moderate inter‐individual variability. Time‐varying body weight and baseline albumin concentration were statistically significant predictors of PK; CL and VC were predicted to increase with increasing body weight, while CL was predicted to decrease with increasing baseline albumin concentration. However, the magnitude of covariate effects is not predicted to meaningfully alter the disposition of sotatercept. Altogether, the PopPK modeling results demonstrate favorable PK characteristics (low to moderate variability and typical bioavailability), supporting sotatercept as a SC biological agent for the treatment of patients with PAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalPulmonary Arterial HypertensionAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultBiological AvailabilityHealthy VolunteersInjections, SubcutaneousRecombinant Fusion ProteinsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Substanzen

Recombinant Fusion Proteins

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • Cognigen Division of Simulations Plus, Inc., Buffalo, New York, USA.
  • Acceleron Pharma, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Sihem Ait-Oudhia, Ziheng Hu, Sébastien Bihorel, Shuai Hu, Janethe de Oliveira Pena, Ferdous Gheyas

Zitieren

APA

Ait-Oudhia, S., Jaworowicz, D., Hu, Z., Bihorel, S., Hu, S., Balasubrahmanyam, B., Mistry, B., de Oliveira Pena, J., Wenning, L., & Gheyas, F. (2024). Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13166

Vancouver

Ait-Oudhia S, Jaworowicz D, Hu Z, Bihorel S, Hu S, Balasubrahmanyam B, et al. Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13166

BibTeX
@article{AitOudhia2024,
  author = {Ait-Oudhia, Sihem and Jaworowicz, David and Hu, Ziheng and Bihorel, Sébastien and Hu, Shuai and Balasubrahmanyam, Budda and Mistry, Bipin and de Oliveira Pena, Janethe and Wenning, Larissa and Gheyas, Ferdous},
  title = {Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13166}
}
Kostenlos starten →